Mesoblast (MESO) “announced gross revenue of $21.9 million on Ryoncil (remestemcel-L-rknd) sales for the quarter ended September 30, 2025. This represents a 66% increase on the prior quarter ended June 30, 2025, with similar gross to net adjustment. Ryoncil is the first mesenchymal stromal cell (MSC) product approved by the U.S. Food and Drug Administration for any indication, and the only product approved for children under age 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD).” CEO Dr. Silviu Itescu said: “We are very pleased with the adoption of Ryoncil(R) to date and with reimbursement by both commercial and government payers. We expect adoption to be further enhanced following the permanent J-Code assigned by Centers for Medicare and Medicaid Services which became active October 1.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MESO:
- Mesoblast receives J-Code for Ryoncil from Medicare & Medicaid Services
- Mesoblast’s U.S. Origin Designation Shields Products from Tariffs
- Largest borrow rate increases among liquid names
- Buy Rating for Mesoblast Driven by Strong Ryoncil Launch and Strategic Financial Moves
- Mesoblast’s Earnings Call Highlights Growth and Challenges